STOCK TITAN

Zai Lab Limited American Depositary Shares - ZLAB STOCK NEWS

Welcome to our dedicated page for Zai Lab American Depositary Shares news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab American Depositary Shares stock.

Zai Lab Limited (NASDAQ: ZLAB) is a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines. Established in 2013 by industry veterans, Zai Lab addresses some of the world's most pressing unmet medical needs with a vision to transform patients’ lives globally.

The company employs a dual approach of in-licensing products and internal research and development to maintain a robust pipeline. This strategy has led to the development of promising drug candidates aimed at treating a range of severe health conditions, particularly in oncology, autoimmune, and infectious diseases.

Core Products and Pipeline:

  • ZL-2306: An investigational treatment for multiple solid tumor types, including ovarian, breast, and lung cancers.
  • ZL-2401: A novel antibiotic belonging to a new class of tetracycline derivatives, significant in the battle against resistant bacterial infections.
  • ZL-2301: An oral small molecule targeting hepatocellular carcinoma (HCC), promising for liver cancer treatment.

Zai Lab's leadership team is acclaimed for their innovative regulatory approval pathways in China, which have expedited the introduction of new therapies. The company's partnerships with global pharmaceutical giants underscore its commitment to conducting world-class clinical development both in China and internationally.

Financially, Zai Lab has strong support from a cadre of leading healthcare investors, ensuring robust backing for its ambitious projects. This financial stability allows the company to explore cutting-edge research and expand its therapeutic offerings continually.

Recent Achievements and Current Projects:

  • Successful initiation of multiple late-stage clinical trials across various therapeutic areas.
  • Establishment of strategic partnerships with multinational pharmaceutical companies to enhance drug development and commercialization.
  • Ongoing expansion of their research facilities to accommodate new projects and collaborations.

Zai Lab remains committed to leveraging its expertise, innovation, and strategic partnerships to bring life-changing therapies to market, ultimately improving patient outcomes worldwide.

Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announces participation in investor conferences in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
-
Rhea-AI Summary
Zai Lab Limited to report Q3 2023 financial results and host conference call and webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
-
Rhea-AI Summary
Zai Lab's efgartigimod SC granted Breakthrough Therapy Designation for CIDP treatment, showing significant efficacy and favorable safety profile
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
Rhea-AI Summary
Zai Lab receives Breakthrough Therapy Designation for repotrectinib in China for the treatment of advanced solid tumors with NTRK gene fusion. The designation supports repotrectinib as a potential first-in-class treatment for patients in China. NTRK is estimated to be an oncogenic driver in approximately 0.5% of patients with advanced solid tumors. Zai Lab looks forward to bringing this important medicine to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
none
-
Rhea-AI Summary
Zai Lab Limited to participate in investor conferences in September 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
-
Rhea-AI Summary
Zai Lab Limited announced financial results for Q2 2023, reporting total product revenue of $68.9 million, a 45% YoY growth. The company received approval in China for VYVGART as the first-and-only FcRn blocker for gMG. They also met the primary endpoint in the ADHERE trial for VYVGART Hytrulo in CIDP. The company has a cash position of $876.4 million as of June 30, 2023. Zai Lab expects significant revenue growth and margin expansion over the next five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
-
Rhea-AI Summary
Zai Lab Limited announces that the Phase 3 PRIME study shows that ZEJULA significantly extends progression-free survival and reduces the risk of disease progression or death by 55% in Chinese patients with newly diagnosed advanced ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary
Zai Lab and argenx announce positive results from the ADHERE study evaluating VYVGART Hytrulo in adults with CIDP. The study met its primary endpoint, demonstrating a significantly lower risk of relapse compared to placebo. Detailed data will be presented at an upcoming medical meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
Rhea-AI Summary
Zai Lab Limited announced the start of the Phase 3 FORTITUDE-101 study for bemarituzumab, a potential treatment for gastric cancer. The study is a global trial sponsored by Amgen and will evaluate the efficacy of bemarituzumab in combination with chemotherapy in patients with untreated advanced gastric cancer. Zai Lab will also participate in the Phase 3 FORTITUDE-102 study in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags

FAQ

What is the current stock price of Zai Lab American Depositary Shares (ZLAB)?

The current stock price of Zai Lab American Depositary Shares (ZLAB) is $25.7 as of November 21, 2024.

What is the market cap of Zai Lab American Depositary Shares (ZLAB)?

The market cap of Zai Lab American Depositary Shares (ZLAB) is approximately 2.7B.

What does Zai Lab Limited specialize in?

Zai Lab Limited focuses on the discovery, development, and commercialization of innovative medicines, particularly in oncology, autoimmune, and infectious diseases.

When was Zai Lab Limited founded?

Zai Lab Limited was founded in 2013 by a team of industry veterans.

What are some key products in Zai Lab's pipeline?

Key products include ZL-2306 for various solid tumors, ZL-2401, a novel antibiotic, and ZL-2301, an oral small molecule targeting hepatocellular carcinoma.

How does Zai Lab Limited approach drug development?

Zai Lab employs a dual approach of in-licensing products and internal R&D to develop a rich pipeline of promising drug candidates.

What recent achievements has Zai Lab Limited made?

Recent achievements include initiating multiple late-stage clinical trials, forming strategic partnerships, and expanding research facilities.

Who are the founders of Zai Lab Limited?

The company was founded by industry veterans known for their contributions to China's biotech industry and their successful regulatory filings.

What partnerships has Zai Lab Limited established?

Zai Lab has developed various partnership models with multinational pharmaceutical companies to enhance drug development and commercialization.

Where does Zai Lab Limited conduct clinical development?

Zai Lab conducts clinical development both in China and internationally.

Who backs Zai Lab Limited financially?

A leading group of healthcare investors provides strong financial backing to Zai Lab Limited.

What is Zai Lab Limited's vision?

Zai Lab aims to address the largest unmet medical needs and transform patients’ lives around the world.

Zai Lab Limited American Depositary Shares

Nasdaq:ZLAB

ZLAB Rankings

ZLAB Stock Data

2.75B
105.32M
1.99%
44.88%
4.68%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SHANGHAI